The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2019 | Optimism for apatinib in gastric cancer
Steven Norton, MBA, PhD, Elevar Therapeutics, Salt Lake City, UT, discusses initial results from the ANGEL study (NCT03042611): the first global trial of apatinib in advanced or metastatic gastric cancer. Dr Norton lists the toxicities seen during the trial but states overall results are promising. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
